Eli Lilly: results, deals and market reaction
What Lilly has reported about its sales, outlook and acquisitions, and what its stock did on the days that mattered. Every figure is dated and linked to where it came from.
Last checked . Figures are company-reported unless a line says otherwise. This is not investment advice. For medicines, trials and approvals see the Eli Lilly tracker.
The 66% is the Atlas's own arithmetic: $16,075 million of $24,397 million. Source for the other figures: Lilly's third-quarter 2026 results release.
Third quarter 2026, reported October 29
Lilly reported revenue of $24,397 million, up 39% from $17,601 million a year earlier. Mounjaro and Zepbound together brought in $16,075 million, up 59% from $10,103 million (the Atlas's sum). Revenue in the United States was about $15.1 billion, up 34%, and outside the United States about $9.3 billion, up 47%.
| Medicine | Q3 2026, $ million | Q3 2025, $ million | Change |
|---|---|---|---|
| Mounjaro (tirzepatide) | 10,723 | 6,515 | +65% |
| Zepbound (tirzepatide) | 5,352 | 3,588 | +49% |
| Foundayo (orforglipron) | 184 | not on sale | new |
| Total Lilly revenue | 24,397 | 17,601 | +39% |
Nine months of 2026: total revenue $67,170 million, up 46%. Mounjaro $29,328 million, up 89%. Zepbound $14,440 million, up 56%. Source: Lilly third-quarter 2026 results release, October 29, 2026.
How Lilly's 2026 outlook has moved
| Date | 2026 revenue outlook | 2026 non-GAAP earnings per share outlook | Source |
|---|---|---|---|
| February 4, 2026 | $80 to $83 billion | Not recorded by the Atlas | Yahoo Finance report of Lilly's guidance |
| Before October 29, 2026 | $85 to $87 billion | $35.50 to $36.50 | Lilly third-quarter release (prior range) |
| October 29, 2026 | $91 to $92 billion | $35.00 to $36.00 | Lilly third-quarter release |
Lilly also raised its expected performance margin to 52.0% to 52.5% from 49.0% to 50.5%, and its expected tax rate to 19% to 20% from 18% to 19%. Lilly said on the call that it will share 2027 guidance with its fourth-quarter results. The Atlas has not confirmed that report's date.
Acquisitions and deals
The third-quarter release names these. None of them is a weight-loss medicine deal, but they explain the research and development charge above.
| Company | What the release says |
|---|---|
| AtaiBeckley | Acquisition completed in the third quarter. The company works on treatment-resistant depression and other mental health conditions. A main driver of the quarter's research and development charge. |
| Curevo | Referenced as a driver of the same charge. |
| Merida Biosciences | Named in the release. The text read by the Atlas describes it in two ways, as completed after quarter end and as an announced acquisition, so the Atlas does not call it closed. |
Obesity deals across the industry are in the deals ledger.
What the stock did
The Atlas records a move only when a named source reported it and says whether the figure is intraday or a close. The “Market that day” column shows how the wider market did, because a share price can move with the market and not with the company's news. It does not host prices or give targets.
On November 5, 2026, U.S. stocks fell sharply (Fox Business reports the Dow down 3.4% at the close), so share moves that day reflect the wider market as well as any company news. The Atlas has not recorded a Lilly or Novo Nordisk move for that day.
| Date | Event | Reported move | Market that day | Source |
|---|---|---|---|---|
| October 29, 2026 | Third-quarter results, outlook raised | About 4% higher before the open (intraday). The Atlas has not found a closing figure. | S&P 500 down 0.3% and Nasdaq down 1.4% at the close, led by a drop in Alphabet. Most S&P 500 stocks rose. | Zacks, October 29, 2026; Associated Press, October 29, 2026 |
| Week to October 31, 2026 | After the results | About 11% higher over the week, to $1,418 a share. | On Friday, October 30, the last session of the week, the S&P 500 fell about 2% and the Nasdaq 2.8%. | TIKR, October 31, 2026; Yahoo Finance, October 30, 2026 |
| February 4, 2026 | 2026 outlook of $80 to $83 billion | Up as much as 10% in midday trading (intraday). Novo Nordisk fell as much as 6% the same day. | S&P 500 down 0.5% and Nasdaq down 1.5% at the close, Dow up 0.5%. | Yahoo Finance, February 4, 2026; Associated Press, February 4, 2026 |
For live quotes use Lilly's investor site or your own brokerage. Nothing on this page says what a share is worth.
Coming up
- December 7, 2026: Lilly Innovation Day, 9:00 AM to 1:00 PM EST, per Lilly's events page.
- With fourth-quarter results: Lilly says it will share 2027 financial guidance. The date has not been confirmed by the Atlas.
Questions about Lilly's results
How much of Lilly's revenue is Mounjaro and Zepbound?
In the third quarter of 2026, Mounjaro ($10,723 million) and Zepbound ($5,352 million) together were about 66% of Lilly's $24,397 million revenue. Both are tirzepatide. Mounjaro is the brand for type 2 diabetes and Zepbound the brand for weight loss and sleep apnea.
Why did Lilly cut its earnings per share outlook while raising sales?
Lilly's release says the change comes from $4.57 per share of acquired research and development charges in the third quarter. Those charges do not change revenue.
Does the Atlas give stock advice?
No. It lists what was reported, with the date and the source. It does not say whether to buy, sell or hold anything, and it does not predict prices.
Where are Lilly's medicines and trials?
In the Eli Lilly tracker. The Novo Nordisk side of the market is on the Novo Nordisk results page.
Sources
- Eli Lilly and Company, third-quarter 2026 results release, October 29, 2026. Company-reported figures.
- Zacks, LLY stock jumps as Q3 earnings beat estimates, 2026 sales view raised, October 29, 2026. Market reporting.
- TIKR, Eli Lilly rallies 11% in a week as Q3 sales jump 39%, October 31, 2026. Market reporting.
- Yahoo Finance, Eli Lilly stock surges after company touts strong sales outlook, February 4, 2026. Market reporting.
- Associated Press, How major US stock indexes fared Thursday 10/29/2026 (copy on La Nación), October 29, 2026. Index closes.
- Associated Press, How major US stock indexes fared Wednesday, 2/4/2026 (copy on WTOP), February 4, 2026. Index closes.
- Yahoo Finance, Stock market today: Nasdaq, Dow, S&P 500 clobbered as October closes with brutal sell-off, October 30, 2026. Index closes.
- Fox Business, Nasdaq tumbles 5%, Dow plunges more than 1,800 points, November 5, 2026. Market reporting.
- Atlas Eli Lilly tracker, including the log of the October 29 earnings call.